Inactive Instrument

News Zymeworks Inc. Toronto S.E.

Equities

ZYME

CA98985W1023

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	Apr. 20	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	Apr. 12	PR
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024	Apr. 11	GL
Zymeworks Inc. Presents New Data from Multiple Preclinical Development Programs At 2024 American Association for Cancer Research Annual Meeting	Apr. 08	CI
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting	Apr. 08	GL
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME	Apr. 04	PR
Zymeworks Inc. Removes Christopher Astle from the Positions of Chief Financial Officer	Apr. 04	CI
Zymeworks Inc. Removes Dr. Christopher Astle from the Positions of Senior Vice President	Apr. 04	CI
Zymeworks Inc. Announces the Composition of the Committees	Mar. 28	CI
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors	Mar. 28	GL
Zymeworks Inc. Announces Appointment of Neil Gallagher to Its Board of Directors and as Member of the Research and Development Committee, Effective April 2, 2024	Mar. 28	CI
Zymeworks Announces Participation in Upcoming Investor Conferences	Mar. 27	GL
Wells Fargo Adjusts Price Target on Zymeworks to $14 From $12, Maintains Overweight Rating	Mar. 12	MT
H.C. Wainwright Adjusts Price Target on Zymeworks to $10 From $8, Maintains Neutral Rating	Mar. 11	MT
Zymeworks Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : Zymeworks Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 06	GL
Zymeworks Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	Mar. 05	GL
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting	Mar. 05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zymeworks Inc. Toronto S.E.

Equities

ZYME

CA98985W1023

Summary

Filters